| Performance Goals | | | Weighting | | | Actual | | | Achieved |
| | | | | • ADCT-901: Advanced trials; completed dose expansion and discontinued due to limited signs of efficacy in dose escalation. Reallocating capital to prioritized programs | | | |||
| | | | | | | ||||
| Advance Non-PBD Early Research Platform in Solid Tumor | | | 15% | | | • Identified multiple targets and advanced several projects towards candidate selection stage | | | 23% |
| | | | | | | ||||
| Extend Cash Runway, Complete Business Development Transaction and Drive Employee Engagement | | | 20% | | | • Extended cash runway into 4Q 2025 by implementing cost reductions and capital allocation strategy • Business Development transaction not yet completed • Employee turnover and engagement achieved at above target | | | 13% |
| TOTAL | | | | | | | 85% |
| Performance Goals | Weighting | Actual | Achieved | ||||||||
| Zynlonta Revenue and Advance Clinical Trials | 40% (25% revenue) | •Achieved $69.1 million in net sales •LOTIS 7: Initiated trial and cleared first dosing cohort with no DLT •LOTIS 5: Progressed the trial and accelerated subject enrollment in 2023 | 24% | ||||||||
| Advance PBD-Based Pipeline on Solid Tumor | 25% | •ADCT-601: Advanced trial; reached MTD and currently in dose optimization •ADCT-901: Advanced trials; completed dose expansion and discontinued due to limited signs of efficacy in dose escalation. Reallocating capital to prioritized programs | 25% | ||||||||
| Advance Non-PBD Early Research Platform in Solid Tumor | 15% | •Identified multiple targets and advanced several projects towards candidate selection stage | 23% | ||||||||
| Extend Cash Runway, Complete Business Development Transaction and Drive Employee Engagement | 20% | •Extended cash runway into 4Q 2025 by implementing cost reductions and capital allocation strategy •Business Development transaction not yet completed •Employee turnover and engagement achieved at above target | 13% | ||||||||
| TOTAL | 85% | ||||||||||
